The Symptoms Of Multiple Sclerosis Blog

The Myelin Repair Foundation and Dalton Pharma Services jointly announce a chemistry collaboration to develop new potential therapeutic compounds for myelin degradation disease states such as Multiple Sclerosis (MS). “We are pleased to have this opportunity to work with the Myelin Repair Foundation engaging our team of experts in medicinal chemistry,

Biogen Idec (NASDAQ: BIIB) today announced the publication of Phase IIb data showing that a 240 mg three-times-daily dose of the company’s novel oral compound, BG-12 (BG00012, dimethyl fumarate), reduced the number of new gadolinium enhancing (Gd+) lesions by 69 percent in patients with relapsing-remitting multiple sclerosis (MS) when compared to treatment with placebo (p

An anthology of original short stories, poetry and personal accounts, MS Talent Volume 2, is set to benefit four charities supporting people with Multiple Sclerosis and raise awareness of the condition, which affects 85,000 people in the UK.

An anthology of original short stories, poetry and personal accounts, MS Talent Volume 2, is set to benefit four charities supporting people with Multiple Sclerosis and raise awareness of the condition, which affects 85,000 people in the UK.

New research may help reveal why different parts of the brain can come under attack in patients with multiple sclerosis (MS). According to a new study in mice with an MS-like disease, the brain’s response to a protein produced by invading T cells dictates whether it’s the spinal cord or cerebellum that comes under fire. The study – from researchers at the University of Maryland School of Medicine in Baltimore and Washington University in St.

A Glasgow-based research lab has announced what it claims to be a major breakthrough in the treatment of progressive multiple sclerosis (MS). Glasgow Health Solutions (GHS), headed by Dr Tom Gilhooly, has developed Tyscore Assay, a blood test which detects the chemicals associated with the deterioration of nerve cells in people with MS.

Scientists at the University of Leeds have developed a hand-held device that they claim can test for serious conditions including multiple sclerosis (MS), using a tiny sample of blood or urine. If trials are successful the researchers hope the technology could be available in three to five years. The device works by looking for tell-tale signs of a condition from the molecules present in the blood (called biomarkers).

A protein that helps keep immune cells quiet is more abundant in the spinal fluid of patients with multiple sclerosis (MS), further boosting suspicion that the protein, TREM-2, may be an important contributor to the disease. More of an immune-control protein might seem like a boon to MS sufferers, whose symptoms are caused by misdirected immune attacks on the protective lining that coats nerve cell branches. But researchers at Washington University School of Medicine in St.